Pharmacy and Therapeutics (P&T) Committee Meeting
Tuesday, February 20th 2018, 6:30 p.m. to 8:00 p.m.

Agenda

**Topic:**

1. Welcome
   - Call to Order
   - Roll Call

2. Conflict of Interest Statement

3. Minutes from Nov 14, 2018 Meeting*

4. Old Business
   - P&T Bylaws
   - Formulary Development and Management at CVS Caremark
   - Recap of The Plan’s 2018 Formulary Strategy

5. Formulary Updates*
   - Hyperinflation Exclusions
   - Tier Changes
     - Specially Designations
     - Negative
     - Positive
   - New Drug Reviews
     - Calquence®
     - Verzenio™
     - Fasenra™
     - Hemlibra®

   - New Policies Under Consideration
     - PPI Limit Policy
     - PPI Post Limit Policy
     - Zegerid® Policy
     - Uloric® Policy
     - Acticlate® Policy

**Presenter:**

- Carl Antolick III, Chair
- Heather Renee Jarnigan, CVS
- Michael Spiritos, MD
- Joseph Shanahan, MD
- David Konanc, MD

*Requires a recommendation from the P&T Committee
• Existing Policies
  o 5-HT1 Agonist Policy
  o Migranal® Policy
  o Butorphanol (Stadol®) Policy
  o Lidocaine Policy

7. Adjourn

- Next Meeting: Tuesday May 22, 2017 from 6:30 to 8:00 PM via webinar